Overview

Definition:
-A choledochal cyst is a congenital cystic dilatation of the bile ducts, most commonly affecting the common bile duct, but can involve intrahepatic ducts
-Intrahepatic stones (choledocholithiasis) within these dilated intrahepatic ducts are a frequent and significant complication, presenting a diagnostic and management challenge.
Epidemiology:
-Rare congenital anomaly, with an estimated incidence of 1 in 100,000 to 1 in 150,000 live births
-More common in East Asian populations, particularly females (4:1 ratio)
-Presentation can occur at any age, from infancy to adulthood, but the pediatric form is most concerning due to early complications.
Clinical Significance:
-Pediatric choledochal cysts with intrahepatic stones pose a significant risk of recurrent cholangitis, pancreatitis, hepatic abscess, portal hypertension, and ultimately, malignant transformation (cholangiocarcinoma), even in children
-Early diagnosis and definitive surgical management are crucial for preventing these severe sequelae and improving long-term outcomes.

Clinical Presentation

Symptoms:
-The classic triad of pain, jaundice, and an abdominal mass is present in less than 20% of pediatric patients
-More common presentations include: Intermittent or persistent abdominal pain, typically in the right upper quadrant
-Recurrent episodes of fever and chills, suggestive of cholangitis
-Jaundice, which may be intermittent or progressive
-Nausea and vomiting
-Poor feeding or failure to thrive in infants
-Clay-colored stools and dark urine
-Palpable abdominal mass (less common).
Signs:
-Right upper quadrant tenderness or a palpable mass
-Hepatosplenomegaly may be present
-Signs of dehydration and sepsis in cases of severe cholangitis
-Icterus of sclera and skin
-Ascites (rare, typically in advanced disease).
Diagnostic Criteria:
-No single definitive diagnostic criterion exists, but a combination of clinical suspicion, biochemical markers, and characteristic imaging findings leads to diagnosis
-Todani's classification system (Type I-V) is widely used to categorize choledochal cysts based on location and extent
-The presence of stones within the dilated intrahepatic ducts further guides management.

Diagnostic Approach

History Taking:
-Focus on duration and nature of abdominal pain, pattern of fever and jaundice, history of recurrent infections, and any previous investigations
-Ask about family history of biliary anomalies
-Screen for red flags: high fever, severe pain, altered consciousness, hematemesis, or melena, indicating complications like sepsis or bleeding.
Physical Examination:
-Thorough abdominal examination for tenderness, guarding, rebound tenderness, and organomegaly
-Assess for icterus and signs of dehydration
-Cardiovascular and respiratory systems should be evaluated for signs of sepsis.
Investigations:
-Liver function tests (LFTs): Elevated total and direct bilirubin, alkaline phosphatase, and GGT
-AST and ALT may be mildly elevated
-White blood cell count is often elevated during cholangitis
-Imaging: Ultrasound is the initial modality of choice, showing cystic dilatation of the bile duct, gallstones, and intrahepatic ductal dilatation
-Magnetic Resonance Cholangiopancreatography (MRCP) is the gold standard for delineating the anatomy, extent of the cyst, and presence/location of stones
-Endoscopic Retrograde Cholangiopancreatography (ERCP) is both diagnostic and therapeutic, allowing for stone extraction and stent placement, but carries higher risks in pediatric patients than MRCP
-CT scan can be helpful in evaluating associated abnormalities or complications like abscesses.
Differential Diagnosis:
-Other causes of pediatric abdominal pain and jaundice, including: Biliary atresia (different pathology, but can coexist or be mistaken initially)
-Viral hepatitis
-Kasai procedure failure
-Gallstones (unusual in pediatric population without risk factors, but possible)
-Pancreatitis
-Appendicitis
-Intussusception
-Ovarian/testicular torsion (in older children).

Management

Initial Management:
-For symptomatic patients with cholangitis: intravenous antibiotics (e.g., piperacillin-tazobactam or ceftriaxone with metronidazole) to cover gram-negative and anaerobic organisms
-Fluid resuscitation and electrolyte correction
-Analgesia
-Nutritional support.
Medical Management:
-Primarily supportive and aimed at managing acute complications like cholangitis
-Long-term medical management is not curative
-surgical intervention is essential.
Surgical Management:
-The cornerstone of treatment
-Complete excision of the extrahepatic bile duct cyst (if present) with a wide Roux-en-Y hepaticojejunostomy is the standard procedure
-Intrahepatic stones are removed during surgery
-Indications for surgery include: Symptomatic cysts (pain, jaundice, cholangitis)
-Asymptomatic cysts with risk of complications
-All choledochal cysts, especially Type I and IV
-For Type III cysts (intraduodenal), endoscopic management may be considered initially
-Radical excision of the cyst and reconstruction with a hepaticojejunostomy prevents stasis, bile duct cancer, and cholangitis.
Supportive Care:
-Postoperative care includes pain management, intravenous fluids, nutritional support (often with parenteral nutrition initially), and monitoring for complications
-Antibiotics may be continued postoperatively if indicated
-Monitoring of LFTs and urine output is essential.

Complications

Early Complications:
-Bleeding from the operative site
-Bile leak from the hepaticojejunostomy
-Cholangitis and sepsis
-Pancreatitis
-Anastomotic stricture
-Wound infection.
Late Complications:
-Intrahepatic ductal stones (recurrent choledocholithiasis)
-Cholangiocarcinoma (lifetime risk is significant, up to 10-15% in some series)
-Portal hypertension due to biliary cirrhosis
-Stricture of the hepaticojejunostomy leading to secondary biliary cirrhosis
-Malabsorption and nutritional deficiencies.
Prevention Strategies:
-Complete and adequate excision of the cyst wall
-Tension-free hepaticojejunostomy
-Prompt diagnosis and surgical management
-Aggressive treatment of cholangitis
-Long-term surveillance for malignancy and complications.

Prognosis

Factors Affecting Prognosis:
-Age at diagnosis and treatment
-Extent and type of cyst
-Presence and management of intrahepatic stones
-Development of complications such as cholangiocarcinoma or biliary cirrhosis
-Quality of surgical reconstruction.
Outcomes:
-With timely and complete surgical treatment, the prognosis is generally good, with most children leading normal lives
-However, the risk of cholangiocarcinoma persists throughout life, necessitating lifelong follow-up
-Recurrence of stones and cholangitis can occur if management is incomplete.
Follow Up:
-Lifelong follow-up is recommended for all patients treated for choledochal cysts
-This includes annual clinical assessment and LFTs
-Periodic imaging (ultrasound or MRCP) may be performed to screen for recurrent stones, strictures, or signs of malignancy
-Patients should be educated about the risk of cholangiocarcinoma and report any new or worsening symptoms promptly.

Key Points

Exam Focus:
-Remember Todani classification and its management implications
-Recognize that intrahepatic stones are a common complication and influence surgical strategy
-Emphasize the lifelong risk of cholangiocarcinoma and the need for surveillance
-Surgical technique of complete excision and Roux-en-Y hepaticojejunostomy is paramount.
Clinical Pearls:
-The "classic triad" is rarely seen in pediatric patients
-suspect choledochal cyst in children with recurrent unexplained abdominal pain, fever, and jaundice
-MRCP is crucial for detailed anatomical assessment and planning
-Aggressive antibiotic management for cholangitis is vital
-Never underestimate the risk of malignancy, even in young patients.
Common Mistakes:
-Incomplete excision of the cyst wall, leading to recurrence or malignancy
-Failure to adequately remove all intrahepatic stones
-Inadequate surgical reconstruction of the biliary-enteric anastomosis
-Delayed diagnosis and management, leading to irreversible liver damage or malignancy
-Underestimating the risk of cholangiocarcinoma in follow-up.